Board of Directors

Carole Ben-Maimon, MD, Chief Executive Officer

Carole Ben-Maimon, MD joined Chondrial Therapeutics in December 2016 as the Chief Executive Officer, bringing more than 25 years experience in the pharmaceutical industry to the company.


Most recently, she worked with Deerfield Management Company assisting in the evaluation of investment opportunities in the brand and generic industry. Prior to working with Deerfield, she was President of Global Pharmaceuticals, a subsidiary of Impax Laboratories that was responsible for Impax’s generic business.


Dr. Ben-Maimon’s career is further highlighted by leadership roles at several pharmaceutical companies including Barr Pharmaceuticals and Teva Pharmaceutical Industries. At Barr Pharmaceuticals, Dr. Ben-Maimon served as President and COO of the company’s branded female healthcare business and was also a member of the Board of Directors. During her tenure at Teva, Dr. Ben-Maimon was responsible for R&D and public policy in North America. In addition to her executive roles, Dr. Ben-Maimon currently serves on the Board of two emerging, privately-held pharmaceutical companies and serves on the Board of a not-for-profit hospital in Philadelphia.


Dr. Ben-Maimon received her B.S. from the University of Pennsylvania and her M.D. from Jefferson Medical College. She completed a residency in internal medicine and a fellowship in nephrology.

R. Mark Payne, MD (CSO) and Co-founder

Dr. Mark Payne, MD, is a co-founder of Chondrial Therapeutics and currently serves as the company’s Chief Scientific Officer. A renowned scientist and practicing physician, Dr. Payne brings to Chondrial a long-standing scientific focus on protein targeting to mitochondria and a dedication to treating cardiomyopathies of childhood, including Friedreich’s Ataxia.


In addition to his role at Chondrial, Dr. Payne is a tenured professor of Pediatrics at Indiana University School of Medicine where he directs multiple training, clinical, and research programs. His lab investigates the role of mitochondrial function in heart disease and is funded by multiple sources, including NIH, AHA, and foundation grants. Previously, while at Wake Forrest University, Dr. Payne conducted extensive research of TAT-transduction technology and was the inventor on the patent, Non-viral Delivery of Proteins to Mitochondria. Dr. Payne also works closely with the patient advocacy group, Friedreich’s Ataxia Research Alliance (FARA), as a scientific advisor, and has significant experience in working with large and small pharmaceutical organizations in basic and clinical research.


Dr. Payne received his BS degree in Natural Sciences from Washington & Lee University, and his MD from the University of Texas at Houston. He performed his clinical training in pediatrics, his fellowship in pediatric cardiology, and a basic research fellowship in molecular biology at Washington University in St. Louis. He is a Fellow of the American College of Cardiology, and a Fellow of the American Academy of Pediatrics.

Tom Hamilton

Tom Hamilton is the current President, CEO and owner of Construction Forms, Inc., an industrial manufacturing company based in Port Washington, WI.  In addition, Tom is also Managing Member of FA Life Sciences, an early stage biotech investment company focused on bridging the gap to cure Friedreich’s Ataxia.  Tom is also a Director and Executive Committee member of the Friedreich’s Ataxia Research Alliance (FARA.)


Prior to Con Forms, Tom was a Managing Director and Strategic Advisor to the Head of Fixed Income, Currencies and Commodities at Barclays Capital in New York, New York. Tom was responsible for the build out of the Global Securitized Products businesses at Barclays along with Municipal Trading and Investment Banking. Prior to Barclays Tom worked at Citigroup Global Markets, and began his career at Salomon Brothers, Inc. in New York.

William Slattery

Bill is a Partner on the Private Transactions team at Deerfield Management Company, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Bill was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Bill has a degree in Biology from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Jonathan Leff

Jonathan is a Partner on the Private Transactions team at Deerfield Management Company and Chairman of the Deerfield Institute. Jonathan joined Deerfield in 2013, and focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to joining Deerfield, for more than 16 years, Jonathan was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals. Jonathan has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), and previously led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC). Jonathan also serves on the Emerging Companies Section Board of the Biotechnology Industry Organization. Jonathan is a member of several not-for-profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, and the Columbia University Medical Center Board of Advisors. Jonathan received his A.B. from Harvard University, and earned his M.B.A. from Stanford Graduate School of Business.

Bryan Sendrowski

Bryan is a Principal on the Private Transactions team at Deerfield Management Company. Bryan joined Deerfield in 2012 and is responsible for the day to day oversight and management of investments in the Deerfield Private Design Funds. Prior to joining Deerfield, Bryan was Chief Financial Officer of New American Therapeutics, a specialty pharmaceutical company that was funded and facilitated by Deerfield’s Private Design Funds. Bryan has over 10 years of experience in the pharmaceutical industry. Prior to New American Therapeutics, Bryan was Chief Financial Officer at Akrimax Pharmaceuticals and Vice President and Controller of Reliant Pharmaceuticals. He also previously served as a Senior Manager in the financial statement audit practice of KPMG, LLP with responsibility for the management of public and private company audits. Mr. Sendrowski received his B.A. from Pace University.

For more information,

contact us today!